SBIR/STTR Research Award

An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease

Award identifier 075e3b0c87878f8f80dafa11e8e4a4a3ea0e74e6eebf6267b41bd827f4231733Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$520,890

Program and phase

STTR · Phase I

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ISCREEN 2 PREVENT, LLC.
Proposal award date
2021-09-01
Contract end date
2022-08-31
UEI
RQE8AAZH6GH3
Solicitation number
PA21-345
Topic code
R

Research abstract

PROJECT SUMMARY In the past decade, the rate of deaths from Alzheimerandapos;s disease (AD) and other dementias escalated more than twice the rate of deaths from heart disease. Unfortunately, there is a lack of low-cost and non-invasive diagnostic instruments to accurately identify individuals at risk of AD and ADRD. Advanced non-invasive imaging shows that retinal neurodegeneration and visual deficits occur long before the cognitive decline in AD and ADRD. This fact raises the possibility of identifying mechanisms that drive retinal pathology in AD/ADRD that could help develop effective diagnostics tools and therapies that target early disease. The well-characterized organization of the retina, with powerful non-invasive imaging and electrophysiology techniques to monitor retinal function, make it an optimal surrogate to study early CNS pathology. The brain shares many similarities with the retina. This suggests that the retina, a more accessible organ than the cortex, may provide a viable brain biomarker for testing diagnostics tools and therapies that target early disease and prevention. Notably, we happen to live in a non-linear world surrounded by objects and processes with the property of fractality and non-linearity. For example, the deficit of fractal complexity (i.e., fractality) of environmental effects can lead to fractal complexity distortion in the brainandapos;s visual pathways and abnormalities of development or aging. Particularly, non-linear dynamics of physiological processes involved in neurodegenerative disorders have a strong base of evidence, which is seen in the impaired fractal regulation of rhythmic activity in aged and diseased brains. Our multivariate biomarker methodology relies on the fractal complexity of the retinal vasculature as a potential biomarker. However, the fractality of the time-varying electroretinogram (ERG) signal that arises from different retina layers is not yet explored. Therefore, we aim to take advantage of the current electrophysiological measurements acquired in the parent grant to investigate the distortion of fractal complexity in ERG signals correlated to AD pathology as a possible means to obtain a more comprehensive assessment for the early detection of MCI due to AD. In this project, we will further innovate our multivariate biomarker methodology by investigating the fractality of ERG signals. This investigation would make our novel method a more robust tool by incorporating the combined fractality of the retinal function (ERG signals) and structure (retinal vasculature), which can shed new light on early pathogenic mechanisms that compromise retinal and brain function much before the onset of detectable dementia. To this end, we will investigate the distortion of fractality in ERG signals and explore the discrimination power of ERGandapos;s fractality measurements between groups with the receiver operating characteristic curve, sensitivity, and specificity metrics. We will use the Youden index and the area under the curve will be calculated for the ERG device calculated features. This project may enable a more comprehensive assessment of aging on ocular and cerebral function at the early stage of cognitive impairment by identifying the most initial signs of complications in the eye and brain using relevant multimodal measures of ocular abnormalities.PROJECT NARRATIVE Alzheimerandapos;s disease is the most common form of dementia among older people. Unfortunately, current diagnostic technologies are limited because they predict cognitive impairment too late and cannot capture various risk or protective factors, increasing healthcare spending. In this project, we aim to investigate the distortion of fractal complexity in electroretinogram (ERG) signals correlated to AD pathology as a possible means to obtain a more comprehensive assessment for the early detection of MCI due to AD.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.